| | Author/year | Country | Study duration | Study design | Adjustments | Results |
| | Wei-Sheng Lee-2016 [15] | Taiwan | 2005–2011 | Case-control | 1, 2, 3, 4, 5, 6, 7, 8, 9 | For SSRIs,
(95% CI: 2.27–2.71)
For MAOIs,
(95% CI: 1.47–2.36)
For TCAs,
(95% CI: 1.32–1.57), | | Wei-Sheng Lee-2017 [16] | Taiwan | 2005–2011 | Case-control | 1, 2, 3, 4, 5, 6, 7, 8, 9 | For SSRIs,
(95% CI: 0.50–0.69)
For TCAs,
(95% CI: 0.89, 1.17
For NGAs,
(95% CI: 3.34, 5.37) | | Wang 2016 [17] | USA | 1991–2010 | Cohort | 1, 2, 3, 6, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18 | For SSRIs,
(95% CI)
For non-SSRIs,
(95% CI) | | Then 2017 [18] | Taiwan | 2003–2006 | Cohort | 1, 2, 3, 4, 8, 9, 19, 20 | For SSRIs,
(95% CI: 2.62–5.09)
For SNRI,
(95% CI: 2.54–8.80)
For TCAs,
(95% CI: 2.30–4.63)
For MAOIs,
(95% CI: 2.17–11.24) | | Goveas 2012 [19] | USA | 1996–2007 | Cohort | 1, 2, 3, 4, 6, 9, 10, 11, 21 | For SSRIs,
(95% CI: 1.01–3.10)
For TCAs,
(95% CI: 0.99–3.21). |
|
|
(1) age, (2) gender, (3) diabetes, (4) hypertension, (5) stroke, (6) coronary artery disease, (7) head injury, (8) anxiety, (9) depression, (10) smoking, (11) body mass index, (12) cancer, (13) COPD, (14) liver disease, (15) hyperlipidemia, (16) renal disease, (17) thyroid disease, (18) cerebrovascular disease, (19) insomnia, (20) CCI, and (21) history of alcohol consumption.
|
